Olema Pharmaceuticals, Inc. 10-Q

Item 5. Other Information. None. 97 Table of Contents Item 6. Exhibits. Incorporated by Reference Exhibit Number Description Schedule Form File Number Exhibit Filing Date 1.1 Sales Agreement by and between Registrant and Cowen and Company, LLC, dated January 5, 2024 8-K 001-39712 1.1 1/5/2024 3.1 Amended and Restated Certificate of Incorporation. 8‑K 001‑39712 3.1 11/23/2020 3.2 Amended and Restated Bylaws. 8‑K 001‑39712 3.1 12/16/2022 10.1* Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Company and Novartis Institutes for BioMedical Research, Inc., dated March 22, 2024. 31.1* Certification of Chief Executive Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Chief Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1*# Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents 104 Cover page formatted as Inline XBRL and contained in Exhibit 101 * Filed herewith. # The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing. 98 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Olema Pharmaceuticals, Inc. Date: May 8, 2024 By: /s/ Sean Bohen, M.D., Ph.D. Sean Bohen, M.D., Ph.D. President and Chief Executive Officer ( Principal Executive Officer ) Date: May 8, 2024 By: /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer ( Principal Financial Officer and Principal Accounting Officer ) 99